
Trine Vik Lagerberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8894319/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Plasma Levels of the Cytokines B Cell-Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) in Schizophrenia, Bipolar, and Major Depressive Disorder: A Cross Sectional, Multisite Study. Schizophrenia Bulletin, 2022, 48, 37-46.	4.3	10
2	Increased circulating IL-18 levels in severe mental disorders indicate systemic inflammasome activation. Brain, Behavior, and Immunity, 2022, 99, 299-306.	4.1	33
3	Affective lability and social functioning in severe mental disorders. European Archives of Psychiatry and Clinical Neuroscience, 2022, , 1.	3.2	3
4	Locked out during COVID-19 lockdown—an online survey of relatives of people with psychotic and bipolar disorders in Norway. BMC Public Health, 2022, 22, 294.	2.9	8
5	Predictors of functional impairment in bipolar disorder: Results from 13 cohorts from seven countries by the global bipolar cohort collaborative. Bipolar Disorders, 2022, 24, 709-719.	1.9	16
6	The COVIDâ€19 pandemic impact on wellbeing and mental health in people with psychotic and bipolar disorders. Brain and Behavior, 2022, 12, e2559.	2.2	15
7	Preventive Medication Patterns in Bipolar Disorder and Their Relationship With Comorbid Substance Use Disorders in a Cross-National Observational Study. Frontiers in Psychiatry, 2022, 13, 813256.	2.6	4
8	Childhood trauma and cardiometabolic risk in severe mental disorders: The mediating role of cognitive control. European Psychiatry, 2021, 64, e24.	0.2	5
9	Substance Misuse Trajectories and Risk of Relapse in the Early Course of Bipolar Disorder. Frontiers in Psychiatry, 2021, 12, 656912.	2.6	4
10	DSM-5 and ICD-11 criteria for bipolar disorder: Implications for the prevalence of bipolar disorder and validity of the diagnosis – A narrative review from the ECNP bipolar disorders network. European Neuropsychopharmacology, 2021, 47, 54-61.	0.7	25
11	Characterizing the Genetic Overlap Between Psychiatric Disorders and Sleep-Related Phenotypes. Biological Psychiatry, 2021, 90, 621-631.	1.3	24
12	Exploring the relationship between recency and frequency of cannabis use and diminished expression and apathy as two dimensions of negative symptoms in first episode psychosis. A one-year follow-up study. Schizophrenia Research, 2021, 236, 89-96.	2.0	4
13	Characterization of affective lability across subgroups of psychosis spectrum disorders. International Journal of Bipolar Disorders, 2021, 9, 34.	2.2	6
14	Disentangling the relationship between cholesterol, aggression, and impulsivity in severe mental disorders. Brain and Behavior, 2020, 10, e01751.	2.2	5
15	The genetic architecture of human brainstem structures and their involvement in common brain disorders. Nature Communications, 2020, 11, 4016.	12.8	26
16	Cannabis Use Is Associated With Increased Levels of Soluble gp130 in Schizophrenia but Not in Bipolar Disorder. Frontiers in Psychiatry, 2020, 11, 642.	2.6	5
17	Polygenic scores for schizophrenia and general cognitive ability: associations with six cognitive domains, premorbid intelligence, and cognitive composite score in individuals with a psychotic disorder and in healthy controls. Translational Psychiatry, 2020, 10, 416.	4.8	16
18	Affective lability across psychosis spectrum disorders. European Psychiatry, 2020, 63, e53.	0.2	17

TRINE VIK LAGERBERG

#	Article	IF	CITATIONS
19	Misperception of sleep in bipolar disorder: an exploratory study using questionnaire versus actigraphy. International Journal of Bipolar Disorders, 2020, 8, 34.	2.2	10
20	Sleep disturbances in schizophrenia spectrum and bipolar disorders – a transdiagnostic perspective. Comprehensive Psychiatry, 2019, 91, 6-12.	3.1	55
21	Validity of the Birchwood insight scale in patients with schizophrenia spectrum- and bipolar disorders. Psychiatry Research, 2019, 272, 715-722.	3.3	8
22	Cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use. European Neuropsychopharmacology, 2018, 28, 37-47.	0.7	13
23	White matter aberrations and age-related trajectories in patients with schizophrenia and bipolar disorder revealed by diffusion tensor imaging. Scientific Reports, 2018, 8, 14129.	3.3	53
24	Course of neurocognitive function in first treatment bipolar I disorder: One-year follow-up study. Psychiatry Research, 2017, 249, 286-292.	3.3	16
25	Impairment in emotion perception from body movements in individuals with bipolar I and bipolar II disorder is associated with functional capacity. International Journal of Bipolar Disorders, 2017, 5, 13.	2.2	22
26	Alcohol use disorders are associated with increased affective lability in bipolar disorder. Journal of Affective Disorders, 2017, 208, 316-324.	4.1	21
27	An exploration of metacognitive beliefs and thought control strategies in bipolar disorder. Comprehensive Psychiatry, 2017, 73, 84-92.	3.1	14
28	History of psychosis and previous episodes as potential explanatory factors for neurocognitive impairment in firstâ€treatment bipolar I disorder. Bipolar Disorders, 2016, 18, 136-147.	1.9	19
29	Duration of untreated illness in first-treatment bipolar I disorder in relation to clinical outcome and cannabis use. Psychiatry Research, 2016, 246, 762-768.	3.3	17
30	Cannabis use is associated with 3 years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N = 1119). Schizophrenia Research, 2016, 170, 217-221.	2.0	47
31	Polygenic risk scores in bipolar disorder subgroups. Journal of Affective Disorders, 2015, 183, 310-314.	4.1	24
32	Continued cannabis use at one year follow up is associated with elevated mood and lower global functioning in bipolar I disorder. BMC Psychiatry, 2015, 15, 11.	2.6	22
33	Affective lability in patients with bipolar disorders is associated with high levels of childhood trauma. Psychiatry Research, 2014, 218, 252-255.	3.3	50
34	Indications of a dose–response relationship between cannabis use and age at onset in bipolar disorder. Psychiatry Research, 2014, 215, 101-104.	3.3	43
35	An association between affective lability and executive functioning in bipolar disorder. Psychiatry Research, 2012, 198, 58-61.	3.3	34
36	Treatment Delay and Excessive Substance Use in Bipolar Disorder. Journal of Nervous and Mental Disease, 2010, 198, 628-633.	1.0	21